Luetkemeyer, Anne F <br/><br/>
Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study.  [electronic resource] 

 -  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America  Jun 2015 
 - 1860-3 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1537-6591 
<br/><br/><label>Standard No.: </label>10.1093/cid/civ155  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Alkynes<br/>Antitubercular Agents--blood<br/>Arylamine N-Acetyltransferase--genetics<br/>Benzoxazines--blood<br/>Cyclopropanes<br/>Cytochrome P-450 CYP2B6--genetics<br/>Female<br/>Genotype<br/>HIV Infections--complications<br/>Humans<br/>Male<br/>Peru<br/>Pharmacogenetics<br/>Rifampin--therapeutic use<br/>South Africa<br/>Tuberculosis--complications<br/>Uganda